American Journal of Kidney Diseases
Volume 54, Issue 6 , Pages 1127-1130 , December 2009

Treatment of Pregabalin Toxicity by Hemodialysis in a Patient With Kidney Failure

  • Lawrence Yoo, MD

      Affiliations

    • Division of Nephrology, New York University Medical Center, New York, NY
    • ,
  • Daniel Matalon, MD

      Affiliations

    • Division of Nephrology, New York University Medical Center, New York, NY
    • New York University School of Medicine, New York, NY
    • ,
  • Robert S. Hoffman, MD

      Affiliations

    • New York University School of Medicine, New York, NY
    • New York City Poison Control Center and Department of Emergency Medicine, New York University Medical Center, New York, NY
    • ,
  • David S. Goldfarb, MD

      Affiliations

    • Division of Nephrology, New York University Medical Center, New York, NY
    • New York University School of Medicine, New York, NY
    • Nephrology Section, New York Harbor VAMC, New York, NY
    • Corresponding Author InformationAddress correspondence to David S. Goldfarb, MD, Nephrology Section/111G, New York DVAMC, 423 E 23 St, New York, NY 10010

Received 6 January 2009 ,Accepted 1 April 2009.

References 

  1. Asconape J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia. 2000;41:479–481
  2. Zhang C, Glenn DG, Bell WL, O'Donovan CA. Gabapentin-induced myoclonus in end-stage renal disease. Epilepsia. 2005;46:156–158
  3. Zareba G. Pregabalin: A new agent for the treatment of neuropathic pain. Drugs Today (Barc). 2005;41:509–516
  4. Olaizola I, Ellger T, Young P, Bosebeck F, Evers S, Kellinghaus C. Pregabalin-associated acute psychosis and epileptiform EEG-changes. Seizure. 2006;15:208–210
  5. Braga AJ, Chidley K. Self-poisoning with lamotrigine and pregabalin. Anaesthesia. 2007;62:524–527
  6. Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia. 2001;42:790–792
  7. Miller R, Frame B, Corrigan B, et al. Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures. Clin Pharmacol Ther. 2003;73:491–505
  8. Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: Lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia. 2005;46:1407–1413
  9. Selak I. Pregabalin (Pfizer). Curr Opin Investig Drugs. 2001;2:828–834
  10. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: A summary of the Fourth Eilat Conference (EILAT IV). Epilepsy Res. 1999;34:1–41
  11. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: A summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 2002;51:31–71
  12. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43:277–283
  13. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(suppl 6):S13–S18
  14. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: A summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res. 2007;73:1–52
  15. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: A randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004;45:20–27
  16. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–1273
  17. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology. 2004;63:2104–2110
  18. Naranjo CA, Busto U, Sellers EM. Difficulties in assessing adverse drug reactions in clinical trials. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6:651–657

 Originally published online as doi:10.1053/j.ajkd.2009.04.014 on June 4, 2009.

 This is a US Government Work. There are no restrictions on its use.

PII: S0272-6386(09)00646-5

doi: 10.1053/j.ajkd.2009.04.014

American Journal of Kidney Diseases
Volume 54, Issue 6 , Pages 1127-1130 , December 2009

Article Tools

* Image Usage & Resolution